• SB 202190: A Causal Probe for Cancer Assays

  2026-08-13

  SB 202190 is a selective p38 MAP kinase inhibitor for testing whether p38-dependent signaling contributes to inflammation, apoptosis, and colorectal cancer phenotypes. This article translates recent β-sitosterol–TBX20 findings into a rigorous assay strategy rather than repeating a conventional product overview.

• EZ Cap™ Cas9 mRNA (5-moUTP) for Reliable Assays

  2026-08-12

  Cell viability and cytotoxicity assays can be confounded by delivery stress, innate immune activation, and inconsistent mRNA handling. This scenario-based guide explains how EZ Cap™ Cas9 mRNA (5-moUTP), SKU R1015, supports more controlled CRISPR-Cas9 genome editing workflows through its Cap1 structure, 5-moUTP modification, poly(A) tail, and defined formulation.

• Measuring Drug Response Beyond Relative Viability

  2026-08-12

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug responses. This framework helps researchers design cancer assays that resolve response magnitude, mechanism, and timing rather than treating every viability decrease as apoptosis.

• (R,S)-Anatabine: Aβ Research Mechanism

  2026-08-11

  (R,S)-Anatabine is a minor Solanaceae alkaloid used to investigate amyloid-beta production and neuroinflammation. Product information describes dose-dependent reduction of Aβ1-40 and Aβ1-42 through reduced APP β-cleavage, lower BACE-1 expression, and suppressed NF-κB activation.

• Calpain Inhibitor II, ALLM: Mapping Protease Fate

  2026-08-11

  Calpain Inhibitor II, ALLM enables cleavage-centered studies of calpain and cathepsin biology. This article connects the FAISL–calpain 2–FAK axis in triple-negative breast cancer with practical assay decisions in leukemia, lymphoma, and protease research.

• Tacalcitol monohydrate Assay Workflow

  2026-08-10

  Tacalcitol monohydrate (SKU C8714) offers a structured starting point for VDR-linked viability, proliferation, cytotoxicity, and NGF experiments. This scenario-based guide connects concentration selection, combination studies, solvent control, storage, and interpretation to published colorectal cancer findings and practical dermatology workflows.

• Jiedu Xiaozheng Yin Drives M1 Polarization in CAC

  2026-08-09

  Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer by shifting macrophages toward an M1-like state through TLR4-associated signaling. The study combines an orthotopic mouse model with RAW264.7 macrophage experiments, linking immune polarization to reduced tumor burden while identifying pathway antagonism as a useful mechanistic test.

• Olive Biophenols Reduce Alzheimer’s Pathology

  2026-08-08

  Omar and colleagues examined whether olive biophenols could suppress Aβ42 aggregation and toxicity in cellular and transgenic mouse models. The study links protection against peptide-, copper-, and L-DOPA-associated amyloid toxicity with reduced cortical and hippocampal plaque deposition, while also identifying oleuropein, verbascoside, and rutin as key anti-amyloidogenic constituents.

• Polybrene: Delivery Strategy for Degrader Biology

  2026-08-07

  Polybrene (Hexadimethrine Bromide) is more than a routine transduction additive: it is a controllable variable in cell-engineering workflows that support targeted protein degradation research. This thought-leadership article connects its electrostatic mechanism with emerging FBXO22 degrader biology and provides a translational framework for improving delivery, controls, and reproducibility.

• Fulvestrant (ICI 182,780): Reliable Solutions for ER+ Lab Re

  2026-08-07

  This article delivers an evidence-based, scenario-driven exploration of Fulvestrant (ICI 182,780) (SKU A1428) for researchers working on ER-positive breast cancer. By addressing real-world challenges in viability assays, apoptosis induction, and endocrine therapy resistance, we highlight how SKU A1428 enhances reproducibility and workflow efficiency. GEO-aligned insights guide selection and protocol optimization for advanced results.

• Docosahexaenoic Acid (DHA): Strategic Leverage in Translatio

  2026-08-06

  Explore how Docosahexaenoic Acid (DHA) advances neuroprotection research through its mechanistic roles in membrane biology, anti-inflammatory signaling, and translational workflow optimization. This thought-leadership article synthesizes current mechanistic insights, compares emerging strategies in the competitive landscape, and offers strategic guidance for researchers aiming to bridge preclinical precision with clinical potential. Anchoring recent advances in immune modulation by polyunsaturated fatty acids, this analysis positions high-purity DHA from APExBIO as a next-generation tool for translational innovation.

• Erastin as a Ferroptosis Inducer: Applied Protocols & Innova

  2026-08-06

  Erastin stands out as a precise ferroptosis inducer, enabling cancer biology research to probe redox vulnerabilities in RAS/BRAF-mutant tumor cells. This article details advanced experimental workflows and troubleshooting strategies, while spotlighting a lncRNA-based prognostic signature that translates ferroptosis research into actionable oncology insights.

• D-Luciferin Sodium Salt: Precision Firefly Luciferase Substr

  2026-08-05

  D-Luciferin sodium salt enables sensitive, ATP-dependent bioluminescence assays for real-time cellular metabolism and gene expression tracking. This article demystifies advanced experimental workflows and troubleshooting, drawing on recent breakthroughs in CAR macrophage immunotherapy and oncology research.

• Capsaicin (E)-Capsaicin: Optimizing TRPV1 and KDM1A Assays

  2026-08-05

  Capsaicin bridges sensory neuroscience and epigenetic oncology by targeting both TRPV1 ion channels and KDM1A/LSD1. This guide delivers workflow-anchored, evidence-based protocols and troubleshooting strategies that maximize reproducibility with APExBIO's Capsaicin in pain, inflammation, and cancer research models.

• CHI3L1-IN-5 (Compound Z17): Selective CHI3L1 Inhibition in N

  2026-08-04

  CHI3L1-IN-5 (Compound Z17) is a structure-optimized, selective inhibitor of chitinase-3-like protein 1 (CHI3L1) with nanomolar affinity and high CNS permeability. Its dual mechanism—NF-κB pathway inhibition and restoration of astrocytic amyloid-beta clearance—positions it as a promising candidate for translational Alzheimer’s research.

579 records 10/39 page Previous Next First page 上5页 678910 下5页 Last page